A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
| Autor: | Reinhard Schneider, Iris Ciba, K. Bergström, Hjalti Kristinsson, Janne Cadamuro, Katharina Mörwald, Joel Kullberg, Hannes Manell, F. B. Lagler, Peter Bergsten, M. Meirik, A. Ladinger, Kirsten Roomp, Susanne M. Brunner, Anders Alderborn, Daniel Weghuber, Anders Forslund, V. Heu, Fanni Zsoldos, Håkan Ahlström, Marie Dahlbom, M. Lidström, Kurt Widhalm, H. Vilen, J. Hofmann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Pediatric Obesity medicine.medical_specialty Adolescent GLP-1 receptor agonist exenatide glucose metabolism pediatric obesity Placebo-controlled study 030209 endocrinology & metabolism Endocrinology and Diabetes Placebo Gastroenterology Pediatrics metabolic syndrome Body Mass Index liver steatosis 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine medicine Humans Child Adverse effect Body mass index 2. Zero hunger 030109 nutrition & dietetics Nutrition and Dietetics business.industry Health Policy Public Health Environmental and Occupational Health Pediatrik Glucose Tolerance Test medicine.disease 3. Good health Clinical trial Tolerability Pediatrics Perinatology and Child Health Endokrinologi och diabetes Exenatide Female Anti-Obesity Agents Metabolic syndrome business medicine.drug |
| Popis: | BACKGROUND: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity. OBJECTIVE: To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. METHODS: Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention. RESULTS: Exenatide reduced (P De två första författarna delar förstaförfattarskapet |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|